

# **PharmaBridge Insights Report**

Generated on: 2025-12-16 13:14:56

## Query

I want to explore repurposing sildenafil for neuropathic pain. Give me a complete analysis including:

- Market opportunity for neuropathic pain
- Patent landscape for sildenafil
- Current clinical trials for sildenafil
- Any internal research we have on sildenafil

## Publications

- Once-Weekly Semaglutide in Adults with Overweight or Obesity — New England Journal of Medicine (2023)
- Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5 — Nature Reviews Endocrinology (2024)

## Clinical Trials

- NCT04566524 — A Research Study to See How Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) (LEAN) [Phase 2] (Recruiting)
- NCT04855081 — A Research Study to See How Well Semaglutide Works in People With Type 2 Diabetes and Chronic Kidney Disease (FLOW) [Phase 3] (Active, not recruiting)

## Patents

- US10251836B2 — Acylated GLP-1 Compounds (exp: 2030-05-15)
- US10722571B2 — Semaglutide Formulations (exp: 2035-03-10)

## Market Insights (IQVIA)

Therapy Area: Metabolic (Obesity/Type 2 Diabetes)  
CAGR: 22.5%  
Market Size: \${'2022': 18.1, '2023': 22.4, '2024': 27.9}M

Key Competitors:

- Semaglutide (Novo Nordisk): 42.0%
- Tirzepatide (Eli Lilly): 28.0%
- Liraglutide (Novo Nordisk): 9.0%
- Oral Agents (SGLT2/DPP4): 14.0%

## Internal Knowledge

- MINS Q3 Field Insights – Obesity Clinics: Clinicians report strong adherence at 12 weeks; nausea management protocols improve persistence.
- Strategy Deck – Incretins Competitive Positioning: Position semaglutide as metabolic platform therapy; defend share vs dual agonists with outcomes data

## Key Insights

- Whitespace: High disease burden with low trial activity